Publication | Closed Access

Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study

MedicineImmunologyPathologyColorectal CancerRepair-deficient Colorectal CancerImmune Checkpoint InhibitorCancer GeneticsMolecular DiagnosticsOncologyNeoadjuvant CamrelizumabMolecular Oncology